SC
XENE icon

Samlyn Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Samlyn Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,016,381
Closed -$34.1M – 100
2025
Q1 		$34.1M Sell
1,016,381
-1,457
-0.1% -$55.3K 0.51% 54
2024
Q4 		$39.9M Sell
1,017,838
-2,368
-0.2% -$97.9K 0.6% 55
2024
Q3 		$40.2M Buy
1,020,206
+380,521
+59% +$15.3M 0.61% 59
2024
Q2 		$24.9M Buy
639,685
+243,489
+61% +$9.73M 0.42% 67
2024
Q1 		$17.1M Sell
396,196
-24,959
-6% -$1.15M 0.29% 81
2023
Q4 		$19.4M Sell
421,155
-530,600
-56% -$18.7M 0.39% 62
2023
Q3 		$32.5M Buy
951,755
+11,846
+1% +$443K 0.53% 59
2023
Q2 		$36.2M Sell
939,909
-219,085
-19% -$8.71M 0.61% 51
2023
Q1 		$41.5M Sell
1,158,994
-34,820
-3% -$1.29M 0.75% 43
2022
Q4 		$47.1M Sell
1,193,814
-95,419
-7% -$3.47M 0.92% 36
2022
Q3 		$46.5M Buy
1,289,233
+172,797
+15% +$6.21M 0.87% 38
2022
Q2 		$34M Buy
1,116,436
+485,707
+77% +$14.7M 0.68% 41
2022
Q1 		$19.3M Buy
630,729
+109,089
+21% +$3.27M 0.28% 73
2021
Q4 		$16.3M Buy
+521,640
New +$15.6M 0.22% 83

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Samlyn Capital's XENE Position: Q2 2025 in Review

Samlyn Capital sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 1,016,381 shares — an estimated $34.1M sold.

Samlyn Capital first reported a position in XENE in Q4 2021 and held it in 14 quarters. The position peaked at $47.1M in Q4 2022. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

  • Samlyn Capital reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Samlyn Capital sold 1,016,381 Xenon Pharmaceuticals shares in Q2 2025, an estimated $34.1M.
  • Samlyn Capital first reported a position in Xenon Pharmaceuticals in Q4 2021 and held it in 14 quarters.
  • Samlyn Capital's Xenon Pharmaceuticals position peaked at $47.1M in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on Samlyn Capital's 13F filing for Q2 2025, filed 14 Aug 2025.